The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1181
ISSUE1181
April 26, 2004
Novoseven for Non-Hemophilia Hemostasis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Novoseven for Non-Hemophilia Hemostasis
April 26, 2004 (Issue: 1181)
Recombinant activated coagulation factor Vll (rFVIIa; NovoSeven - Novo Nordisk), which is marketed worldwide for treatment of bleeding episodes in hemophilia patients with inhibitors to factor VIII or IX, is now being used off-label to stop bleeding...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.